Overview: ROS1 TestIntroduction: The ROS1 Test tests for ROS1 gene rearrangements to diagnose lung or other cancers, helping guide targeted therapy for abnormal cell growth. Affecting 1 in 100 people with lung cancer, ROS1 rearrangements pose diagnostic challenges due to rarity. Following 2023 National Comprehensive Cancer Network (NCCN) guidelines, it uses FISH/PCR for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in oncology.
Other Names: ROS1 Rearrangement Test, Lung Cancer Gene Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: ROS1 testing began in the 2010s with research by Bergethon, who identified the rearrangement. FISH/PCR advancements by Abbott Molecular improved detection, surpassing earlier sequencing methods.
Purpose: Detects ROS1 rearrangement status to diagnose lung or other cancers, guides tyrosine kinase inhibitors, and evaluates patients with respiratory symptoms, aiming to manage disease.
Test Parameters: ROS1 rearrangement status
Pretest Condition: Tissue biopsy required. Collect tissue or whole blood. Report history of cancer.
Specimen: Tissue (FFPE, 0.5-2 cma³), Whole Blood (EDTA, 3-5 mL); Tissue in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document cancer history or respiratory symptoms. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., metastasis), and sample collection risks.
Procedural Considerations: Uses FISH/PCR to detect rearrangements, requiring labs with fluorescence microscopes or thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive rearrangement confirms cancer, guiding therapy. Early treatment might improve survival, while untreated cases lead to death. Normal results may require other tests.
Specialist Consultation: Consult an oncologist for interpretation.
Additional Supporting Tests: Biopsy, CT scan, or EGFR test to confirm diagnosis.
Test Limitations: Specific to ROS1; correlation with clinical status needed. False negatives possible with untested variants.
References: NCCN Guidelines, 2023; Journal of Thoracic Oncology, Bergethon K, 2022.
